Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib

Qin, Bo; Xin, Lingli; Hou, Qingxiang; Yang, Bo; Zhang, Jing; Qi, Xin; Wei, Yingtian; Hu, Yi; Xiong, Qi

doi:10.1002/cam4.3941

Cited by 4 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After reading the full-text of the remaining 19 studies, 6 of them were further excluded as they were ongoing clinical trials and/or clinical trial designs. Finally, the remaining 13 studies [17][18][19][20][21][22][23][24][25][26][27][28][29] were included for this meta-analysis. The process of literature screening is shown in Figure 1.…”

Section: Literature Search Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis

Cao

Jie

et al. 2022

Tumori

View full text Add to dashboard Cite

Background: Anlotinib is one of the tyrosine kinase inhibitors that exhibits promising anti-tumor effect in several cancers. However, the efficacy and safety of anlotinib in pre-treated small cell lung cancer (SCLC) is not well determined. Herein, we performed this meta-analysis to summarize the effectiveness and safety of anlotinib in the treatment of pre-treated SCLC. Methods: The databases, such as PubMed and Embase, were searched to identify eligible studies. Clinical studies reporting the efficacy and safety of anlotinib in the treatment of patients with pre-treated SCLC were included. The main endpoints were overall survival (OS), progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), and adverse events. The Review Manager 5.4 and STATA 14 statistical software were used to perform the meta-analysis. Results: A total of 13 studies were included, involving 779 patients with SCLC. The ORR and DCR for the anlotinib group were 0.21 (95%CI: 0.12- 0.31; p < 0.01) and 0.76 (95%CI: 0.69- 0.83; p < 0.01), respectively. The summarized PFS and OS for the anlotinib group were 3.46 (95%CI: 2.68-4.24), and 6.86 (95%CI: 5.79-7.93) months, respectively. Compared with control group, the PFS in the anlotinib group was significantly longer standard mean difference(SMD)=0.76, 95%CI: 0.11, 1.41; p = 0.02). In terms of safety, the most common grade 3 or higher adverse events in the anlotinib group were hypertension (9%; 95%CI: 6%-13%), hand-foot syndrome (6%; 95%CI: 2%-9%), and fatigue (4%; 95%CI: 2%-7%). Conclusions: Anlotinib may be associated with favorable efficacy outcomes in pre-treated SCLC patients with acceptable safety.

show abstract

Section: Literature Search Resultsmentioning

confidence: 99%

“…In this meta-analysis, there were 8 retrospective studies with single arms, [18][19][20][21][22]25,26,28 3 retrospective studies 17,24,29 with two arms, and 2 RCTs 23,27 with anlotinib versus control arms. This meta-analysis involved 779 patients.…”

Section: Baseline Characteristics Of the Included Studiesmentioning

confidence: 99%

The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis

Cao

Jie

et al. 2022

Tumori

View full text Add to dashboard Cite

show abstract

“…Therefore, it is important to screen the benefit population of anlotinib treatment by methods. Recently, three retrospective studies about SCLC treatment with anlotinib had tried to select some ways to identify those benefit patients, which indicated that the response to first‐line treatment, 22 prognostic nutritional indexes, 11 and tumor cavitation 9 could predict survival independently, yet all through relatively simple means. Our team once established a system of risk scores by different combinations of multiple inflammatory indicators in NSCLC, which was capable of predicting the best population for anlotinib treatment 7 .…”

Section: Discussionmentioning

confidence: 99%

“…The PFS resulting from this research was similar to another related retrospective study (mPFS: 2.6 months). 9 However, while Recently, three retrospective studies about SCLC treatment with anlotinib had tried to select some ways to identify those benefit patients, which indicated that the response to first-line treatment, 22 prognostic nutritional indexes, 11 and tumor cavitation 9 could predict survival independently, yet all through relatively simple means.…”

Section: Discussionmentioning

confidence: 99%

Inflammation‐based prognostic scoring system for predicting the prognosis of advanced small cell lung cancer patients receiving anlotinib monotherapy

Chen

Tang

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background: According to the randomized multicenter phase II trial (ALTER1202), anlotinib has been approved as a third-line therapy for advanced small-cell lung cancer (SCLC). Some studies showed the predictive function of inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in the different cancers treated with antivascular targeting drugs. However, none of the studies showed the roles of NLR, PLR, and LMR in SCLC patients receiving anlotinib. Thus, our objective was to establish a scoring system based on inflammation to individuate patient stratification and selection based on NLR, PLR, and LMR.Methods: NLR, PLR, and LMR and their variations were calculated in 53 advanced SCLC patients receiving anlotinib as a third-or further-line treatment at Ningbo

show abstract

“…The ALTER-0303 phase III randomized clinical trial confirmed the effectiveness and safety of anlotinib as a third-line treatment in patients with NSCLC (Han et al, 2018). It was reported that anlotinib could improve the survival of patients diagnosed with advanced lung cancer, either NSCLC or small-cell lung cancer (SCLC) (Li et al, 2021;Qin et al, 2021). A real-world study conducted by Zhang K. et al (2020) also confirmed the efficacy and safety of anlotinib in advanced NSCLC patients.…”

Section: Introductionmentioning

confidence: 88%

Efficacy and Safety of Drug-Eluting Bead Bronchial Arterial Chemoembolization Plus Anlotinib in Patients With Advanced Non-small-Cell Lung Cancer

Liu

Zhang

Ren

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Aim: The aim of this study is to determine the efficacy and safety of the combination therapy of drug-eluting bead bronchial arterial chemoembolization plus anlotinib oral administration in the treatment of non-small-cell lung cancer (NSCLC).Methods: Consecutive data from 51 patients with advanced NSCLC were retrospectively collected from February 2018 to August 2019. All patients underwent drug-eluting bead bronchial arterial chemoembolization (DEB-BACE) followed by anlotinib treatment. Overall survival (OS) and progression-free survival (PFS) were calculated and analyzed using the Kaplan–Meier method and log-rank test, and factors associated with OS and PFS were assessed by a Cox proportional hazards test. Treatment response at 30 days was assessed by enhanced computed tomography (CT), and then the objective response rate (ORR) and disease control rate (DCR) were calculated. Treatment-related adverse events (TRAEs) were also evaluated.Results: The median OS was 18.4 months (95% CI, 16.6–20.2 months), and the median PFS was 8.4 months (95% CI, 6.2–10.6 months). The ORR and DCR for the whole cohort were 21.6 and 100%, respectively, at 30 days after the first cycle of treatment. Most of the treatment-related adverse reactions were mild and moderate and included anorexia, hypertension, fatigue, and hand-foot syndrome. Only eight (15.7%) patients developed grade 3 TRAEs. No deaths or other serious adverse reactions occurred. Both TNM stage and brain metastasis were independent risk factors for OS and PFS.Conclusion: DEB-BACE concomitant with anlotinib has promising efficacy and tolerable toxicity in patients with advanced NSCLC.

show abstract

Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 4 publications

References 26 publications

The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis

The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis

Inflammation‐based prognostic scoring system for predicting the prognosis of advanced small cell lung cancer patients receiving anlotinib monotherapy

Efficacy and Safety of Drug-Eluting Bead Bronchial Arterial Chemoembolization Plus Anlotinib in Patients With Advanced Non-small-Cell Lung Cancer

Contact Info

Product

Resources

About